• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)-A European Society of Organ Transplantation (ESOT) Consensus Statement.原发性硬化性胆管炎(PSC)伴或不伴炎症性肠病(IBD)的肝移植-欧洲器官移植学会(ESOT)共识声明。
Transpl Int. 2023 Sep 29;36:11729. doi: 10.3389/ti.2023.11729. eCollection 2023.
2
The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis.原发性硬化性胆管炎肝移植术后炎症性肠病的影响。
Liver Int. 2013 Jan;33(1):53-61. doi: 10.1111/j.1478-3231.2011.02677.x. Epub 2011 Nov 22.
3
Asymptomatic De Novo Inflammatory Bowel Disease Late After Liver Transplantation for Primary Sclerosing Cholangitis: A Case Report.肝移植治疗原发性硬化性胆管炎后晚期出现的无症状性新发炎症性肠病:一例报告
Transplant Proc. 2015 Nov;47(9):2775-7. doi: 10.1016/j.transproceed.2015.09.043.
4
Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis.原发性硬化性胆管炎肝移植术后炎症性肠病患者的结直肠癌
Transplantation. 2003 Jun 27;75(12):1983-8. doi: 10.1097/01.TP.0000058744.34965.38.
5
Activity of Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis Predicts Poorer Clinical Outcomes.原发性硬化性胆管炎行肝移植后炎症性肠病的活动度预测更差的临床结局。
Inflamm Bowel Dis. 2020 Nov 19;26(12):1901-1908. doi: 10.1093/ibd/izz325.
6
Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series.原发性硬化性胆管炎肝移植受者中抗 TNF 治疗炎症性肠病的疗效和安全性:一项全国性病例系列研究。
Dig Liver Dis. 2018 Jul;50(7):668-674. doi: 10.1016/j.dld.2018.02.014. Epub 2018 Mar 13.
7
Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis.原发性硬化性胆管炎肝移植后炎症性肠病。
Am J Gastroenterol. 2013 Sep;108(9):1417-25. doi: 10.1038/ajg.2013.163. Epub 2013 Jul 30.
8
Epidemiology and outcomes of primary sclerosing cholangitis with and without inflammatory bowel disease in an Australian cohort.澳大利亚队列中伴或不伴炎症性肠病的原发性硬化性胆管炎的流行病学和结局。
Liver Int. 2017 Mar;37(3):442-448. doi: 10.1111/liv.13328. Epub 2017 Jan 24.
9
Inflammatory bowel disease in liver transplanted patients.肝移植患者中的炎症性肠病
World J Gastroenterol. 2017 May 14;23(18):3214-3227. doi: 10.3748/wjg.v23.i18.3214.
10
Clinical management of inflammatory bowel disease in the organ recipient.器官移植受者炎症性肠病的临床管理
World J Gastroenterol. 2014 Apr 7;20(13):3525-33. doi: 10.3748/wjg.v20.i13.3525.

引用本文的文献

1
Bioengineered Bile Duct for Liver Regenerative Medicine and Bile Duct Reconstruction.用于肝脏再生医学和胆管重建的生物工程胆管
JGH Open. 2025 Aug 12;9(8):e70254. doi: 10.1002/jgh3.70254. eCollection 2025 Aug.
2
T and B cell responses against Epstein-Barr virus in primary sclerosing cholangitis.原发性硬化性胆管炎中针对爱泼斯坦-巴尔病毒的T细胞和B细胞反应
Nat Med. 2025 Jun 11. doi: 10.1038/s41591-025-03692-w.
3
2024: A Year in Review.2024年回顾
Transpl Int. 2025 Jan 14;37:14243. doi: 10.3389/ti.2024.14243. eCollection 2024.
4
Primary sclerosing cholangitis in children with inflammatory bowel disease: An ESPGHAN position paper from the Hepatology Committee and the IBD Porto group.炎症性肠病患儿的原发性硬化性胆管炎:欧洲儿科胃肠病、肝病和营养学会肝病委员会及炎症性肠病波尔图小组的立场文件
J Pediatr Gastroenterol Nutr. 2025 Feb;80(2):374-393. doi: 10.1002/jpn3.12378. Epub 2024 Dec 31.
5
Pulmonary hypertension post-liver transplant: A case report.肝移植术后肺动脉高压:一例报告。
World J Gastrointest Surg. 2024 Dec 27;16(12):3875-3880. doi: 10.4240/wjgs.v16.i12.3875.
6
Outcome of Liver Retransplantation in Patients With Primary Sclerosing Cholangitis.原发性硬化性胆管炎患者肝再次移植的结果
Liver Int. 2025 Jan;45(1):e16214. doi: 10.1111/liv.16214.
7
Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host-Microbiome-Metabolomic Signatures.原发性硬化性胆管炎-炎症性肠病中开放标签万古霉素治疗:结肠疾病活动改善及与宿主-微生物组-代谢组学特征变化的关联
J Crohns Colitis. 2025 Feb 4;19(2). doi: 10.1093/ecco-jcc/jjae189.
8
De Novo Kaposi Sarcoma in an HIV-Negative Liver Transplant Recipient With Ulcerative Colitis and Primary Sclerosing Cholangitis.一名患有溃疡性结肠炎和原发性硬化性胆管炎的HIV阴性肝移植受者新发卡波西肉瘤
Case Rep Transplant. 2024 Nov 12;2024:4699128. doi: 10.1155/crit/4699128. eCollection 2024.
9
Colorectal cancer in ulcerative colitis after liver transplantation for primary sclerosing cholangitis: a systematic review and pooled analysis of oncological outcomes.原发性硬化性胆管炎肝移植术后溃疡性结肠炎患者的结直肠癌:肿瘤学结局的系统评价和汇总分析
Discov Oncol. 2024 Oct 8;15(1):529. doi: 10.1007/s12672-024-01304-6.
10
The Impact of Biliary Injury on the Recurrence of Biliary Cancer and Benign Disease after Liver Transplantation: Risk Factors and Mechanisms.肝移植术后胆管损伤对胆管癌及良性疾病复发的影响:危险因素与机制
Cancers (Basel). 2024 Aug 7;16(16):2789. doi: 10.3390/cancers16162789.

本文引用的文献

1
ESOT Consensus Platform for Organ Transplantation: Setting the Stage for a Rigorous, Regularly Updated Development Process.ESOT 器官移植共识平台:为严格、定期更新的开发过程奠定基础。
Transpl Int. 2022 Oct 24;35:10915. doi: 10.3389/ti.2022.10915. eCollection 2022.
2
The microbiota and the gut-liver axis in primary sclerosing cholangitis.原发性硬化性胆管炎中的微生物群与肠-肝轴
Nat Rev Gastroenterol Hepatol. 2023 Mar;20(3):135-154. doi: 10.1038/s41575-022-00690-y. Epub 2022 Nov 9.
3
Bile Duct Colonization With Enterococcus sp. Associates With Disease Progression in Primary Sclerosing Cholangitis.肠球菌定植于胆管与原发性硬化性胆管炎的疾病进展相关。
Clin Gastroenterol Hepatol. 2023 May;21(5):1223-1232.e3. doi: 10.1016/j.cgh.2022.09.006. Epub 2022 Sep 16.
4
EASL Clinical Practice Guidelines on sclerosing cholangitis.欧洲肝脏研究学会肝硬化临床实践指南。
J Hepatol. 2022 Sep;77(3):761-806. doi: 10.1016/j.jhep.2022.05.011. Epub 2022 Jun 21.
5
Impact of ulcerative colitis on liver-related outcomes of children with primary sclerosing cholangitis.溃疡性结肠炎对原发性硬化性胆管炎患儿肝脏相关结局的影响。
J Paediatr Child Health. 2022 Jul;58(7):1221-1227. doi: 10.1111/jpc.15954. Epub 2022 Apr 4.
6
Mucosal immunity in primary sclerosing cholangitis: from the bowel to bile ducts and back again.原发性硬化性胆管炎中的黏膜免疫:从肠道到胆管再回归肠道
Curr Opin Gastroenterol. 2022 Mar 1;38(2):104-113. doi: 10.1097/MOG.0000000000000809.
7
Sclerosing Cholangitis in Pediatric Inflammatory Bowel Disease: Early Diagnosis and Management Affect Clinical Outcome.儿童炎症性肠病中的硬化性胆管炎:早期诊断和治疗对临床结局有影响。
J Pediatr. 2021 Nov;238:50-56.e3. doi: 10.1016/j.jpeds.2021.07.047. Epub 2021 Jul 23.
8
Recent advances in clinical practice: epidemiology of autoimmune liver diseases.临床实践新进展:自身免疫性肝病的流行病学。
Gut. 2021 Oct;70(10):1989-2003. doi: 10.1136/gutjnl-2020-322362. Epub 2021 Jul 15.
9
Risk Prediction Models for Postoperative Decompensation and Infection in Patients With Cirrhosis: A Veterans Affairs Cohort Study.肝硬化患者术后失代偿和感染的风险预测模型:退伍军人事务队列研究。
Clin Gastroenterol Hepatol. 2022 May;20(5):e1121-e1134. doi: 10.1016/j.cgh.2021.06.050. Epub 2021 Jul 8.
10
Stent versus Balloon Dilation for the Treatment of Dominant Strictures in Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis.支架与球囊扩张术治疗原发性硬化性胆管炎主要狭窄的系统评价与Meta分析
Clin Endosc. 2021 Nov;54(6):833-842. doi: 10.5946/ce.2021.052. Epub 2021 Jul 1.

原发性硬化性胆管炎(PSC)伴或不伴炎症性肠病(IBD)的肝移植-欧洲器官移植学会(ESOT)共识声明。

Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)-A European Society of Organ Transplantation (ESOT) Consensus Statement.

机构信息

Centre for Autoimmune Liver Diseases, Department of Medicina and Surgery, University of Milano-Bicocca, Milan, Italy.

European Reference Network on Hepatological Diseases (ERN RARE-LIVER), IRCCS San Gerardo dei Tintori, Monza, Italy.

出版信息

Transpl Int. 2023 Sep 29;36:11729. doi: 10.3389/ti.2023.11729. eCollection 2023.

DOI:
10.3389/ti.2023.11729
PMID:37841645
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10570452/
Abstract

Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD) and a lead indication for liver transplantation (LT) in the western world. In this article, we present a Consensus Statement on LT practice, developed by a dedicated Guidelines' Taskforce of the European Society of Organ Transplantation (ESOT). The overarching goal is to provide practical guidance on commonly debated topics, including indications and timing of LT, management of bile duct stenosis in patients on the transplant waiting list, technical aspects of transplantation, immunosuppressive strategies post-transplant, timing and extension of intestinal resection and futility criteria for re-transplantation.

摘要

原发性硬化性胆管炎(PSC)是炎症性肠病(IBD)的经典肝胆表现,也是西方世界进行肝移植(LT)的主要指征。在本文中,我们提出了一份由欧洲器官移植学会(ESOT)专门的指南工作组制定的关于 LT 实践的共识声明。总体目标是就常见争议话题提供实用指导,包括 LT 的适应证和时机、移植等待名单上患者胆管狭窄的管理、移植技术方面、移植后免疫抑制策略、肠道切除术的时机和范围以及再次移植的无效标准。